Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer

Radiotherapy and Oncology

Volumn 115, Issue 3, 2015, Pages 367-372

  Nguyen, Quynh Nhu ^a   Ly, Ngoc Bui ^a   Komaki, Ritsuko ^a   Levy, Lawrence B ^a   Gomez, Daniel R ^a   Chang, Joe Y ^a   Allen, Pamela K ^a   Mehran, Reza J ^a   Lu, Charles ^a   Gillin, Michael ^a   Liao, Zhongxing ^a   Cox, James D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Carboplatin; Disease control; Paclitaxel; Passive scattering; Proton beam therapy; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; PACLITAXEL;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; DERMATITIS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON THERAPY; RADIATION DOSE; RADIATION PNEUMONIA; ADULT; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; ESOPHAGITIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTON THERAPY; TREATMENT OUTCOME;

EID: 84942822471     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.05.014     Document Type: Article

References (21)

1. D.A. Bush, G. Cheek, S. Zaheer, and et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12 year experience at Loma Linda University Medical Center Int J Radiat Biol Phys 86 2013 964 968
2. A. Kanemoto, T. Okumura, H. Ishikawa, and et al. Outcomes and prognostic factors for recurrence after high-dose proton beam therapy for centrally and peripherally located stage I non-small cell lung cancer Clin Lung Cancer 15 2014 7 12
3. H. Nakayama, H. Satoh, S. Sugahara, and et al. Proton beam therapy of stage II and III non-small cell lung cancer Int J Radiat Oncol Biol Phys 81 2011 979 984
4. B.S. Hoppe, S. Flampouri, R.H. Henderson, and et al. Proton therapy with concurrent chemotherapy for non-small cell lung cancer: technique and early results Clin Lung Cancer 13 2012 352 358
5. J.Y. Chang, R. Komaki, C. Lu, and et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer Cancer 117 2011 4707 4713
6. M. Yang, R. Zhu, P.C. Park, and et al. Comprehensive analysis of proton range uncertainties related to patient stopping-power-ratio estimation using the stoichiometric calibration Phys Med Biol 57 2012 4095 4115
7. J.Y. Chang, L. Dong, H. Liu, and et al. Image-guided radiation therapy for non-small cell lung cancer J Thorac Oncol 3 2008 177 186
8. M. Machtay, K. Bae, B. Movsas, and et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 82 2012 425 434
9. M.A. Socinski, A.W. Blackstock, J.A. Bogart, and et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small cell lung cancer: CALGB 30105 J Clin Oncol 26 2008 2457 2463
10. J.D. Bradley, J. Moughan, M.V. Graham, and et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I-III non-small cell lung cancer: phase I results of RTOG 0117 Int J Radiat Oncol Biol Phys 77 2010 367 372
11. K.E. Rosenzweig, J.L. Fox, E. Yorke, and et al. Results of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non small cell lung carcinoma Cancer 103 2005 2118 2127
12. M.A. Socinski, D.E. Morris, J.S. Halle, and et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small cell lung cancer: a dose-escalation phase I trial J Clin Oncol 22 2004 4341 4350
13. M.A. Socinski, J.G. Rosenman, J. Halle, and et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B non-small cell lung carcinoma: a modified phase I/II trial Cancer 92 2001 1213 1223
14. J.D. Bradley, P. Paulus, and R. Komaki Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study Lancet Oncol 16 2015 187 199
15. J.D. Cox Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys 82 2012 1042 1044
16. PORT Meta-analysis Trialists Group Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials Lancet 352 1998 257 263
17. PORT Meta-analysis Trialists Group Postoperative radiotherapy for non-small cell lung cancer Cochrane Database Syst Rev 2 2005 CD002142
18. C. Billiet, H. Decaluwé, S. Peeters, and et al. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis Radiother Oncol 110 2014 3 8
19. L. Zhao, B.T. West, J.A. Hayman, S. Lyons, K. Cease, and F.M. Kong High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer Int J Radiat Oncol Biol Phys 68 2007 103 110
20. M. Baumann, T. Herrmann, R. Koch, and et al. CHARTWEL-Bronchus study group. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC) Radiother Oncol 100 2011 76 85 10.1016/j.radonc.2011.06.031 (Epub 2011 Jul 13)
21. M. Soliman, A. Yaromina, S. Appold, and et al. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial Radiother Oncol 106 2013 299 304 10.1016/j.radonc.2012.12.008 (Epub 2013 Jan 17)